Does treatment with bisphosphonates protect against fractures in real life? The HUNT study, Norway.
Anti-osteoporotic drugs
Cohort study
Fractures
General population studies
HUNT
Osteoporosis
Journal
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
04
09
2020
accepted:
11
01
2021
pubmed:
23
1
2021
medline:
16
6
2021
entrez:
22
1
2021
Statut:
ppublish
Résumé
Bisphosphonates reduce fractures in randomized controlled trials (RCT); however, there is less information from real life. In our population including 14,990 women and 13,239 men, use of bisphosphonates reduced risk of fractures in hip and forearm in women. The magnitude of the effect was comparable to results from RCT. The objective was to examine if treatment with bisphosphonates (BPs) was associated with reduced risk of fractures in the hip and forearm in women and men in the general population. In a cohort study based on data from the third wave of the population-based HUNT Study (HUNT3), the fracture registry in Nord-Trøndelag, and the Norwegian Prescription Database, 14,990 women and 13,239 men 50-85 years were followed from the date of participating in HUNT3 (2006-2008) until the date of first fracture in the hip or forearm, death, or end of study (31 December 2012). Hazard ratios with 95% confidence intervals for hip and forearm fracture according to use of BPs were estimated using Cox proportional hazards models with time-dependent exposure. Adjustment for individual FRAX® fracture risk assessment scores was included. BPs, predominantly alendronate, were used by 9.4% of the women and 1.5% of the men. During a median of 5.2 years of follow-up, 265 women and 133 men had a hip fracture, and 662 women and 127 men had a forearm fracture. Compared with non-users of BPs, the hazard ratios with 95% confidence interval for a fracture among users of BPs adjusted for age and FRAX® were 0.67 (0.52-0.86) for women and 1.13 (0.50-2.57) for men. Among users of glucocorticoids, the corresponding figures were 0.35 (0.19-0.66) and 1.16 (0.33-4.09), respectively. Use of BPs was associated with reduced risk of fractures in hip and forearm in women, and the magnitude of effect is comparable to results from RCTs.
Identifiants
pubmed: 33479844
doi: 10.1007/s00198-021-05845-2
pii: 10.1007/s00198-021-05845-2
pmc: PMC8192327
doi:
Substances chimiques
Diphosphonates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1395-1404Références
(1993) Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94(6):646–650. https://doi.org/10.1016/0002-9343(93)90218-e
Black DM, Rosen CJ (2016) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 374(3):254–262. https://doi.org/10.1056/NEJMcp1513724
doi: 10.1056/NEJMcp1513724
pubmed: 26789873
Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393(10169):364–376. https://doi.org/10.1016/S0140-6736(18)32112-3
doi: 10.1016/S0140-6736(18)32112-3
pubmed: 30696576
Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Suttorp MJ, Motala A, Ewing B, Roth B, Shanman R, Timmer M, Shekelle PG (2012) Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. Rockville MD
Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161(10):711–723. https://doi.org/10.7326/M14-0317
doi: 10.7326/M14-0317
pubmed: 25199883
Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155. https://doi.org/10.1002/14651858.CD001155.pub2
doi: 10.1002/14651858.CD001155.pub2
Strom O, Lauppe R, Ljunggren O, Spangeus A, Ortsater G, O'Kelly J, Akesson K (2020) Real-world effectiveness of osteoporosis treatment in the oldest old. Osteoporos Int 31(8):1525–1533. https://doi.org/10.1007/s00198-020-05380-6
doi: 10.1007/s00198-020-05380-6
pubmed: 32232509
pmcid: 7360659
Yusuf AA, Cummings SR, Watts NB, Feudjo MT, Sprafka JM, Zhou J, Guo H, Balasubramanian A, Cooper C (2018) Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Arch Osteoporos 13(1):33. https://doi.org/10.1007/s11657-018-0439-3
doi: 10.1007/s11657-018-0439-3
pubmed: 29564735
pmcid: 5862911
Reyes C, Pottegard A, Schwarz P, Javaid MK, Van Staa TP, Cooper C, Diez-Perez A, Abrahamsen B, Prieto-Alhambra D (2016) Real-life and RCT participants: alendronate users versus FITs’ trial eligibility criterion. Calcif Tissue Int 99(3):243–249. https://doi.org/10.1007/s00223-016-0141-7
doi: 10.1007/s00223-016-0141-7
pubmed: 27099132
Wang YK, Zhang YM, Qin SQ, Wang X, Ma T, Guo JB, Zhu C, Luo ZJ (2018) Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 97(42):e12691. https://doi.org/10.1097/MD.0000000000012691
doi: 10.1097/MD.0000000000012691
Allen CS, Yeung JH, Vandermeer B, Homik J (2016) Bisphosphonates for steroid-induced osteoporosis. Cochrane Database System Rev 10(10):Cd001347. https://doi.org/10.1002/14651858.CD001347.pub2
doi: 10.1002/14651858.CD001347.pub2
Olsen KR, Hansen C, Abrahamsen B (2013) Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. Osteoporos Int 24(10):2639–2647. https://doi.org/10.1007/s00198-013-2365-y
doi: 10.1007/s00198-013-2365-y
pubmed: 23604250
Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R (2016) Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ 353:i3365. https://doi.org/10.1136/bmj.i3365
doi: 10.1136/bmj.i3365
pubmed: 27353596
pmcid: 4924596
Nordstrom P, Toots A, Gustafson Y, Thorngren KG, Hommel A, Nordstrom A (2017) Bisphosphonate use after hip fracture in older adults: a Nationwide retrospective cohort study. J Am Med Dir Assoc 18(6):515–521. https://doi.org/10.1016/j.jamda.2016.12.083
doi: 10.1016/j.jamda.2016.12.083
pubmed: 28238673
Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, Abrahamsen B, Schei B (2015) Use of anti-osteoporotic drugs in Central Norway after a forearm fracture. Arch Osteoporos 10:235. https://doi.org/10.1007/s11657-015-0235-2
doi: 10.1007/s11657-015-0235-2
pubmed: 26334427
Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, Skovlund E, Abrahamsen B, Forsmo S, Schei B (2018) Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway. Osteoporos Int 29(8):1875–1885. https://doi.org/10.1007/s00198-018-4560-3
doi: 10.1007/s00198-018-4560-3
pubmed: 29774403
Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ (2010) Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway. Eur J Clin Pharmacol 66(3):299–306. https://doi.org/10.1007/s00228-009-0746-0
doi: 10.1007/s00228-009-0746-0
pubmed: 19898839
Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https://doi.org/10.1007/s11657-013-0136-1
doi: 10.1007/s11657-013-0136-1
pubmed: 24113837
pmcid: 3880487
Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, Bratberg G, Heggland J, Holmen J (2013) Cohort profile: the HUNT study, Norway. Int J Epidemiol 42(4):968–977. https://doi.org/10.1093/ije/dys095
doi: 10.1093/ije/dys095
pubmed: 22879362
Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Asvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Juni P, Aujesky D, Rodondi N, Thyroid Studies C (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313(20):2055–2065. https://doi.org/10.1001/jama.2015.5161
doi: 10.1001/jama.2015.5161
pubmed: 26010634
pmcid: 4729304
Hoff M, Skovlund E, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, Forsmo S, Abrahamsen B, Schei B (2020) Proton pump inhibitors and fracture risk. The HUNT study, Norway. Osteoporosis Int 31(1):109–118. https://doi.org/10.1007/s00198-019-05206-0
doi: 10.1007/s00198-019-05206-0
Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD) – new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiol 129–136
Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX and its applications to clinical practice. Bone 44(5):734–743. https://doi.org/10.1016/j.bone.2009.01.373
doi: 10.1016/j.bone.2009.01.373
pubmed: 19195497
Hoff M, Meyer HE, Skurtveit S, Langhammer A, Sogaard AJ, Syversen U, Dhainaut A, Skovlund E, Abrahamsen B, Schei B (2017) Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. Osteoporos Int 28(10):2935–2944. https://doi.org/10.1007/s00198-017-4134-9
doi: 10.1007/s00198-017-4134-9
pubmed: 28668994
Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12(9):809–824. https://doi.org/10.1002/sim.4780120902
doi: 10.1002/sim.4780120902
pubmed: 8327801
Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ (2012) Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf 21(3):297–304. https://doi.org/10.1002/pds.2344
doi: 10.1002/pds.2344
pubmed: 22237942
Iglay K, Cao X, Mavros P, Joshi K, Yu S, Tunceli K (2015) Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy. Clin Ther 37(8):1813–1821.e1811. https://doi.org/10.1016/j.clinthera.2015.05.505
doi: 10.1016/j.clinthera.2015.05.505
pubmed: 26117406
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535–1541. https://doi.org/10.1016/s0140-6736(96)07088-2
doi: 10.1016/s0140-6736(96)07088-2
pubmed: 8950879
van de Glind EM, Willems HC, Eslami S, Abu-Hanna A, Lems WF, Hooft L, de Rooij SE, Black DM, van Munster BC (2016) Estimating the time to benefit for preventive drugs with the statistical process control method: an example with alendronate. Drugs Aging 33(5):347–353. https://doi.org/10.1007/s40266-016-0344-7
doi: 10.1007/s40266-016-0344-7
pubmed: 26884390
pmcid: 4837200
Abrahamsen B (2017) The emperor redressed: treating osteoporosis to prevent hip fractures in the oldest old. J Intern Med 282(6):560–562. https://doi.org/10.1111/joim.12700
doi: 10.1111/joim.12700
pubmed: 29030888
Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339(5):292–299. https://doi.org/10.1056/NEJM199807303390502
doi: 10.1056/NEJM199807303390502
pubmed: 9682041
Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30(6):1145–1156. https://doi.org/10.1007/s00198-019-04906-x
doi: 10.1007/s00198-019-04906-x
pubmed: 30805679
Raterman HG, Bultink IEM, Lems WF (2019) Current treatments and new developments in the management of glucocorticoid-induced osteoporosis. Drugs 79(10):1065–1087. https://doi.org/10.1007/s40265-019-01145-6
doi: 10.1007/s40265-019-01145-6
pubmed: 31201710
Bultink IE, Vis M, van der Horst-Bruinsma IE, Lems WF (2012) Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep 14(3):224–230. https://doi.org/10.1007/s11926-012-0252-8
doi: 10.1007/s11926-012-0252-8
pubmed: 22477520
pmcid: 3338911
Bultink IE, Baden M, Lems WF (2013) Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 14(2):185–197. https://doi.org/10.1517/14656566.2013.761975
doi: 10.1517/14656566.2013.761975
pubmed: 23317448
Levesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087. https://doi.org/10.1136/bmj.b5087
doi: 10.1136/bmj.b5087
pubmed: 20228141
Mackey DC, Black DM, Bauer DC, McCloskey EV, Eastell R, Mesenbrink P, Thompson JR, Cummings SR (2011) Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res 26(10):2411–2418. https://doi.org/10.1002/jbmr.446
doi: 10.1002/jbmr.446
pubmed: 21710615